Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 48094 - shoulder prosthesis screw - device manufactured from titanium alloy and enhanced with type-ii anodization. they are designed to aid fixation of the glenoid baseplate to bone. device intended for use as a hemi or total shoulder replacement. it is a single-use device for the reconstruction of the gleno-humeral joint in case of osteoarthritis, rheumatoid arthritis, traumatic arthritis, avascular necrosis as well as complex fractures, post-traumatic malunion and revision of failed arthroplasty in patients with an intact or reparable rotator cuff shoulder joint. the humeral components are for cemented and cementless use.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 48093 - reverse shoulder prosthesis head - the glenosphere is attached to the glenoid baseplate and secured by a taper connection and a fastening screw. the centre of the glenosphere is located at 4 or 9mm lateral to the deepest point of the reamed glenoid vault, while the inferior eccentricity is fixed at 2mm throughout the whole glenosphere range. the inferior offset reduces the risk of scapular notching, while the two options of lateralization allow the surgeon to select the desired level of rom and joint tension. device indicated for treatment of humeral fractures and for primary or revision total shoulder replacement in patients with a grossly rotator cuff deficient shoulder joint with severe arthropathy or a previously failed joint replacement. the patient?s joint must be anatomically and structurally suited to receive the selected implant(s), and a functional deltoid muscle is necessary to use the device. the glenoid baseplate is intended for cementless application with the addition of screws for fixation.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 39702 - coated shoulder humeral stem prosthesis - the device is manufactured from titianium. the shape of the humeral diaphysis devices was developed to be anatomical and provide a stable positioning in the canal, especially in the calcar region. fixation is achieved without the use of cement; stability is fostered by a titanium plasma spray and hydroxyapatite coating in the metaphyseal region. the devices can be used in anatomic and reverse configurations using either the anatomic metaphysis or the reverse metaphysis. device intended for use as a hemi or total shoulder replacement. it is a single-use device for the reconstruction of the gleno-humeral joint in case of osteoarthritis, rheumatoid arthritis, traumatic arthritis, avascular necrosis as well as complex fractures, post-traumatic malunion and revision of failed arthroplasty in patients with an intact or reparable rotator cuff shoulder joint.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 48092 - reverse shoulder prosthesis cup - the humeral reverse hc liner has a 5? wedged shape and can be coupled with the humeral reverse metaphysis in two orientations: depending on the joint?s stability of the single patient, the surgeon can intraoperatively decide between an inclination of 145?, which allows for a wider range of motion at the cost of a reduced stability in total adduction, or 155?, which is associated to a higher stability and reduced range of motion. device indicated for treatment of humeral fractures and for primary or revision total shoulder replacement in patients with a grossly rotator cuff deficient shoulder joint with severe arthropathy or a previously failed joint replacement. the patient?s joint must be anatomically and structurally suited to receive the selected implant(s), and a functional deltoid muscle is necessary to use the device. the glenoid baseplate is intended for cementless application with the addition of screws for fixation.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 60511 - reverse shoulder prosthesis body - the device is manufactured from titanium is used with the humeral diaphysis cementless implant. it is designed as an inset adapter to prevent excessive distalisation of the humerus and over-tensioning of the deltoid, and to reduce the lever arm during shoulder abduction. the device is fixed to the humeral diaphysis cementless implant with a locking screw. device indicated for treatment of humeral fractures and for primary or revision total shoulder replacement in patients with a grossly rotator cuff deficient shoulder joint with severe arthropathy or a previously failed joint replacement. the patient?s joint must be anatomically and structurally suited to receive the selected implant(s), and a functional deltoid muscle is necessary to use the device.

İsrail - İngilizce - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 50 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

İsrail - İngilizce - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 100 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

İsrail - İngilizce - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 150 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

İsrail - İngilizce - Ministry of Health

tzamal bio-pharma ltd - 5-aminolevulinic acid as hydrochloride - powder for solution - 5-aminolevulinic acid as hydrochloride 1.5 g - aminolevulinic acid - aminolevulinic acid - gliolan® is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (who grade iii and iv).